These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 8486569)
21. [In vitro antibacterial activity of cefpirome: a new cephalosporin; results of a multicenter study]. Soussy CJ; Chanal M; Derlot E; Goldstein F; Duval J Pathol Biol (Paris); 1994 Oct; 42(8):754-60. PubMed ID: 7724247 [TBL] [Abstract][Full Text] [Related]
22. In vitro activity of cefpirome compared with other third generation cephalosporins against nosocomial isolates in Argentina. Casellas JM; Goldberg M; Orellana N; Morosini MI; Negri MC; Arduino S Infection; 1990; 18(3):193-5. PubMed ID: 2114372 [TBL] [Abstract][Full Text] [Related]
23. The antimicrobial activity of cefpirome, a new cephalosporin. Wise R; Andrews JM; Cross C; Piddock LJ J Antimicrob Chemother; 1985 Apr; 15(4):449-56. PubMed ID: 3874198 [TBL] [Abstract][Full Text] [Related]
24. [Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase]. López-Yeste M; Xercavins M; Lite J; Cuchí E; Garau J Enferm Infecc Microbiol Clin; 1996 Apr; 14(4):211-4. PubMed ID: 9044634 [TBL] [Abstract][Full Text] [Related]
25. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp. Baltch AL; Smith RP; Ritz W Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822 [TBL] [Abstract][Full Text] [Related]
26. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Sader HS; Jones RN Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):675-9. PubMed ID: 7813503 [TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Lewis MT; Yamaguchi K; Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 1999 Dec; 35(4):307-15. PubMed ID: 10668590 [TBL] [Abstract][Full Text] [Related]
28. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. Neu HC; Chin NX; Jules K; Labthavikul P J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862 [TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. Biedenbach DJ; Johnson DM; Jones RN Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589 [TBL] [Abstract][Full Text] [Related]
30. In-vitro activity of cefpirome compared with that of other agents. Raizes EG; Cantey JR J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388 [TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group. Lewis MT; Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 1999 Dec; 35(4):317-23. PubMed ID: 10668591 [TBL] [Abstract][Full Text] [Related]
32. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria. Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706 [TBL] [Abstract][Full Text] [Related]
33. Beta-lactamase stability and antibacterial activity of cefpirome alone and in combination with other antibiotics. Bakhtiar M; Selwyn S Drugs Exp Clin Res; 1989; 15(10):477-82. PubMed ID: 2698794 [TBL] [Abstract][Full Text] [Related]
34. beta-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria. Piddock LJ; Traynor EA J Antimicrob Chemother; 1991 Aug; 28(2):209-19. PubMed ID: 1778852 [TBL] [Abstract][Full Text] [Related]
35. [Activity of fourth generation cephalosporins against clinical isolates of Enterobacteriaceae]. Tuchiluş C; Poiată A; Bădicuţ I; Teodor A; Luca V; Grigore L; Buiuc D Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):595-8. PubMed ID: 14756068 [TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients. Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance. Murray PR; Niles AC Diagn Microbiol Infect Dis; 1986 Jan; 4(1):53-63. PubMed ID: 3632921 [TBL] [Abstract][Full Text] [Related]
39. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa. Watanabe N; Hiruma R; Katsu K J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980 [TBL] [Abstract][Full Text] [Related]
40. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group. Biedenbach DJ; Johnson DM; Jones RN Diagn Microbiol Infect Dis; 1999 Dec; 35(4):325-31. PubMed ID: 10668592 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]